Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock

Published 23/09/2022, 16:05
Updated 23/09/2022, 16:40
© Reuters.  Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock

The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.

Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform.

Nu Skin Enterprises

  • The Trade: Nu Skin Enterprises, Inc. (NYSE: NUS) Director Andrew D Lipman sold a total of 1,000 shares at an average price of $36.67. The insider received around $36.67 thousand from selling those shares.
  • What’s Happening: The company, last month, posted downbeat quarterly earnings.
  • What Nu Skin Enterprises Does: Nu Skin Enterprises Inc is a health and beauty direct-selling company with a comprehensive product line: anti-aging skin products; peels, masks, and scrubs; moisturizers; body care; hair care; men's care; oral care; sun protection; and cosmetics.
Also check this: Darden Restaurants To Gain 7%? Here Are 5 Other Price Target (NYSE:TGT) Changes For Friday

Bristol-Myers Squibb Company (NYSE:BMY)

  • The Trade: Bristol-Myers Squibb Company (NYSE: BMY) Board Chair and CEO Giovanni Caforio sold a total of 25,000 shares at an average price of $69.71. The insider received around $1.74 million as a result of the transaction.
  • What’s Happening: The European Commission approved Bristol Myers Squibb’s fixed-dose combination of Opdualag (nivolumab and relatlimab) for melanoma patients aged 12 years and above.
  • What Bristol-Myers Squibb Does: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders.
Have a look at our premarket coverage here .

Nasdaq

  • The Trade: Nasdaq, Inc. (NASDAQ: NDAQ) Executive Vice President Jeremy Skule sold a total of 2,100 shares at an average price of $59.80. The insider received around $125.58 thousand from selling those shares.
  • What’s Happening: In an apparent bid to tap into the growing lure of high-net-worth individuals into the crypto space, Nasdaq will offer custody services for Bitcoin and Ethereum to institutional investors.
  • What Nasdaq Does: Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%).
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.